Patrick Daly

DocwireNews

According to a poster at the 2022 American Society of Clinical Oncology, the combination of the anti-CD47 monoclonal antibody, magrolimab, with azacitidine was well-tolerated and demonstrated promising efficacy in patients with untreated higher-risk myelodysplastic syndromes (MDS). The phase 1b study was led by David Andrew Sallman, MD, from the Moffitt Cancer Center in Tampa, FL.In a cohort of 95 patients with untreated intermediate-, high-, or very-high-risk MDS, Dr. Sallman and colleagues administered a priming dose of intravenous magrolimab 1 mg/kg, followed by a ramp-up to a maintenance dose 30 mg/kg once weekly or every other week. The primary measures of the study were safety, tolerability, and the rate of complete remission (CR).Among the patients, 27%, 52%, and 21% had intermediate, high, or very-high IPSS-R risk. Additionally, 22% had therapy-related MDS, 26% had a TP53 mutation, and 62% had poor-risk cytogenetics. The rate of mortality at 60 days was 2%, the rate of CR was 33%, and the rate of objective response was 75%. According to the investigators, the median time to first OR, duration of CR, duration of OR, and progression-free survival (PFS) was 1.9, 11.1, 9.8, and 11.6 months, respectively.The most commonly reported treatment-emergent adverse events (TEAEs) included constipation (68%), thrombocytopenia (55%), anemia (52%), neutropenia (47%), nausea (46%), and diarrhea (44%). Grade III and IV TEAEs included anemia (47%), neutropenia (46%), thrombocytopenia (46%), and white blood cell count decrease (30%).Ultimately, the authors presented their data in support of the use of magrolimab with azacitidine in patients with treatment-na&iuml;ve higher-risk MDS. For further reference, they pointed to the ongoing phase III ENHANCE trial on magrolimab or placebo with azacitidine.

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Jordana Jampel

Actress Michelle Trachtenberg's Premature Death From Diabetes Reveals Dangers of Chronic Complications

Diabetes

Latest News

Evaluating the Combination of Anti-CD47 Antibodies and HMAs for Higher-Risk MDS

ASCO 2022

According to a poster at the 2022 American Society of Clinical Oncology, the combination of the anti-CD47 monoclonal antibody, magrolimab, with azacitidine was well-tolerated ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe